Cingulate Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
CING$4.45+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | ||||
|---|---|---|---|---|
| Exhibit Number | Exhibit Description | Form | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation of Cingulate Inc., as amended to date | S-1 | 3.1 | 1/12/2024 |
| 3.2 | Amended and Restated Bylaws of Cingulate Inc. | 10-K | 3.2 | 3/28/2022 |
| 4.1 | Form of January 2024 WFIA Pre-Funded Warrant | 8-K | 4.1 | 1/29/2024 |
| 4.2 | Form of February 2024 Pre-Funded Warrant | 8-K | 4.1 | 2/7/2024 |
| 4.3 | Form of February 2024 Series A Warrant | 8-K | 4.2 | 2/7/2024 |
| 4.4 | Form of February 2024 Series B Warrant | 8-K | 4.3 | 2/7/2024 |
| 4.5 | Form of February 2024 Placement Agent Warrant | 8-K | 4.4 | 2/7/2024 |
| 4.6 | Form of March 2024 WFIA Pre-Funded Warrant | 10-K | 4.16 | 4/1/2024 |
| 10.1 | Employment Agreement, dated January 25, 2024, between Cingulate Therapeutics LLC, and Jennifer L. Callahan | 8-K | 10.2 | 1/29/2024 |
| 10.2 | Amendment to Employment Agreement, effective January 1, 2024, between Cingulate Therapeutics, LLC and Matthew N. Brams | S-1 | 10.26 | 1/12/2024 |
| 10.3 | Note Conversion Agreement, dated January 25, 2024, by and between the Company, Cingulate Therapeutics, LLC and Werth Family Investment Associates LLC | 8-K | 10.1 | 1/29/2024 |
| 10.4 | Form of February 2024 Securities Purchase Agreement | 8-K | 10.1 | 2/7/2024 |
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |||
| 32.1** | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||
| 32.2** | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||
| 101.INS* | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema | |||
| 101.CAL* | Inline XBRL Extension Calculation Linkbase | |||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase | |||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase | |||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase | |||
| 104* | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) | |||
- Filed Herewith
** Furnished Herewith
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.